Biomedical company Femasys Inc. (FEMY) Wednesday announced positive data from its FemaSeed localized directional insemination for artificial insemination pivotal trial.
The company said the trial investigated its FemaSeed product that enhances fertilization in women with a variety of infertility factors with the primary efficacy analysis focused on the severe male factor infertility. FemaSeed could help precisely deliver sperm into the fallopian tube, the natural site of conception.
The company expects that the FDA-approved FemaSeed could be positioned as a first-line treatment option, prior to costly and invasive assisted reproductive procedures, such as IVF and ICSI.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.